Identification of 9-fluoro substituted (-)-cytisine derivatives as ligands with high affinity for nicotinic receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6667-6670

  Houllier, Nicolas ^a   Gopisetti, Jaganmohan ^a   Lestage, Pierre ^b   Lasne, Marie Claire ^a   Rouden, Jacques ^a  

^a 6 Bd du Maréchal Juin   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Fluoro substituted cytisine; Ligands; Nicotinic receptors

Indexed keywords

9 BROMOCYTISINE; 9 FLUOROCYTISINE; 9 METHYLCYTISINE; 9 TRIFLUOROMETHYLCYTISINE; CYTISINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG IDENTIFICATION; DRUG SELECTIVITY; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

EID: 77958031654     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.017     Document Type: Article

References (56)

1. N.J. Leonard R.H.F. Manske, H.L. Holmes, The Alkaloids Vol. 3 1953 Academic Press New York 119 199
2. O'Neill, B. T. Pyridone-Fused Azabicyclic- or Cytisine derivatives, their Preparation and their Use in Addiction Therapy.
3. (a) PCT Int. Appl. 1998, WO9818,798,1998
4. Chem. Abstr. 1998, 119, 4774k
5. (b) U.S. Patent 6,235,734B1, 2001.
6. C. Canu Boido, and F. Sparatore Farmaco 54 1999 438
7. E. Marrire, J. Rouden, V. Tadino, and M.-C. Lasne Org. Lett. 2 2000 1121
8. D.J. Anderson, and S.P. Arneric Eur. J. Pharmacol. 253 1994 261
9. L.A. Pabreza, S. Dhawan, and K. Kellar J. Mol. Pharmacol. 39 1991 9
10. R.A. Glennon, and M. Dukat Med. Chem. Res. 1996 465
11. M. Hall, L. Zerbe, S. Leonard, and R. Freedman Brain Res. 600 1993 127
12. For reviews, see: M.W. Holladay, M.J. Dart, and J.K. Lynch J. Med. Chem. 40 1997 4169
13. M.N. Romanelli, P. Gratteri, L. Guandalini, E. Martini, C. Bonaccini, and F. Gualtieri ChemMedChem 2 2007 746
14. J.A. Dani, and D. Bertrand Annu. Rev. Pharmacol. Toxicol. 47 2007 699
15. C. Gotti, M. Zoli, and F. Clementi Trends Pharmacol. Sci. 27 2006 482
16. J. Lindstrom J. Mol. Neurobiol. 15 1997 193
17. 3-Substituted (-)-cytisines: C. Canu Boido, B. Tasso, V. Boido, and F. Sparatore Farmaco 58 2003 265
18. B. Tasso, C. Canu Boido, E. Terranova, C. Gotti, L. Riganti, F. Clementi, R. Artali, G. Bombieri, F. Meneghetti, and F. Sparatore J. Med. Chem. 52 2009 4345
19. 6-Substituted (-)-cytisines: J. Rouden, A. Ragot, S. Gouault, D. Cahard, J.-C. Plaquevent, and M.-C. Lasne Tetrahedron: Asymmetry 13 2002 1299
20. N. Houllier, S. Gouault, M.-C. Lasne, and J. Rouden Tetrahedron 6 2006 11679
21. 10-Substituted (-)-cytisines: S.K. Chellappan, Y. Xiao, W. Tueckmantel, K.J. Kellar, and A.P. Kozikowski J. Med. Chem. 49 2006 2673
22. A.P. Kozikowski, S.K. Chellapan, Y. Xiao, K.M. Bajjuri, H. Yuan, K.J. Kellar, and P.A. Petukhov ChemMedChem 2 2007 1157
23. Kozikowski, A. P.; Tueckmantel, W.; Chellappan, S.; Kellar, K. J.; Xiao, Y. 10-Substituted cytisine derivatives and methods of use thereof. PCT Int. Appl. WO 2007 115092 A2 20071011, 2007.
24. A.P. Kozikowski, J.B. Eaton, K.M. Bajjuri, S.K. Chellappan, Y.H. Chen, S. Karadi, R. He, B. Caldarone, M. Manzano, P.W. Yuen, and R.J. Lukas ChemMedChem 4 2009 1279
25. 9 and 11-substituted-(-)-cytisines, i.e.: P. Imming, P. Klaperski, M.T. Stubbs, G. Seitz, and D. Gündisch Eur. J. Med. Chem. 36 2001 375
26. G. Roger, B. Lagnel, J. Rouden, L. Besret, H. Valette, S. Demphel, J. Gopisetti, C. Coulon, M. Ottaviani, L.A. Wrenn, S.R. Letchworth, G.A. Bohme, J. Benavides, M.-C. Lasne, Bottlaender, and F. Dollé Bioorg. Med. Chem. 11 2003 5333
27. Y.E. Slater, L.M. Houlihan, P.D. Maskell, R. Exley, I. Bermudez, R.J. Lukas, A.C. Valdivia, and B.K. Cassels Neuropharmacology 44 2003 503
28. E. Carbonnelle, F. Sparatore, C. Canu-Boido, C. Salvagno, B. Baldani-Guerra, G. Terstappen, R. Zwart, H. Vijverberg, F. Clementi, and C. Gotti Eur. J. Pharmacol. 471 2003 85
29. R.W. Fitch, Y. Kaneko, P. Klaperski, J.W. Daly, G. Seitz, and D. Gündisch Bioorg. Med. Chem. Lett. 15 2005 1221
30. C.A. Zambrano, M.J. Marks, B.K. Cassels, and R.B. Maccioni Neuropharmacology 57 2009 332
31. Y. Charton, C. Guillonneau, B. Lockhart, P. Lestage, and S. Goldstein Bioorg. Med. Chem. Lett. 18 2008 2188
32. K.L. Kirk Org. Process. Res. Dev. 12 2008 305
33. O'Hagan, D. J. Fluorine Chem. doi:10.1016/j.jfluchem.2010.03.003.
34. G. Balz, and G. Schiemann Chem. Ber. 60 1927 1186
35. G.S. Lal, G.P. Pez, and R.G. Syvret Chem. Rev. 96 1996 1737
36. S.G. Taylor, C.C. Kotoris, and G. Hum Tetrahedron 55 1999 12431
37. R.E. Banks J. Fluorine Chem. 87 1998 1
38. 3·326.1441, found 326.1451.
39. 3 308,1535, found 308.1525.
40. 3 308,1535, found 308.1525.
41. 2O 208.1011, found 208.1032.
42. 2O 208,10117, found 208,10166.
43. K. Matsui, E. Tobita, M. Ando, and K. Kondo Chem. Lett. 1981 1719
44. G.E. Carr, R.D. Chambers, and T.F. Holmes J. Chem. Soc., Perkin 1 1988 921
45. H. Suzuki, Y. Yoshida, and A. Osuka Chem. Lett. 1982 135
46. 3 359.1583, found 359.1573.
47. 2O 259.1058, found 259.1070.
48. 3 305.1865, found 305.1875.
49. 2O 205.1341, found 205.1305.
50. 125I]alpha-bungarotoxin (2 nM) for 5 h at 37 °C. Non-specific binding was assessed by the incubation of membrane preparations with 1 μM alpha-bungarotoxin. Pabreza, L. A.; Dhawan, S.; Kellar, K. Mol. Pharmacol. 1990, 39, 9, and Ref. 15.
51. J.A. Abin-Carriquiry, M.H. Voutilainen, J. Barik, B.K. Cassels, P. Iturriaga-Vasquez, I. Bermudez, C. Durand, F. Dajas, and S. Wonnacott Eur. J. Pharmacol. 536 2006 1
52. 2 nAChRs.
53. F. Leroux, P. Jeschke, and M. Schlosser Chem. Rev. 105 2005 827
54. M.-C. Lasne, C. Perrio, J. Rouden, L. Barré, D. Roeda, F. Dollé, and C. Crouzel W. Krause, Topics in Current Chemistry Vol. 222 2002 Springer Berlin 201 258 and references therein
55. G. Antoni, T. Khilberg, and B. Lngström M.J. Welch, C.S. Redvanly, Handbook of Radiopharmaceuticals. Radiochemistry and Applications 2003 Wiley Chichester, UK 141 194
56. I. Bennacef, C. Perrio, M.-C. Lasne, and L. Barré J. Org. Chem. 72 2007 2161 and references therein